Dyne Therapeutics, Inc. (NASDAQ: DYN) is a Healthcare company (Biotechnology) with a market capitalization of $3.0B. The Maz Rating grades it against the other companies in its sector.
Dyne Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.02, Dyne Therapeutics, Inc. trades at 3.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -69.7%, return on invested capital of -52.8% and a free cash flow yield of -18.9%. On the balance sheet: a debt-to-equity ratio of 0.26 and a current ratio of 12.99. Over the past 52 weeks the share price ranged from $14.00 to $27.31, with a beta of 1.21.
Dyne Therapeutics, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 1 Strong Buy, 10 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Dyne Therapeutics, Inc. (DYN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 7.12% / 30% · (Cash+Inv) / Mkt Cap (36m) 35.8% / 30% · Interest income / Revenue 976700000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 7.12% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 35.8% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 976700000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 7.12% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 35.8% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 976700000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 6.34% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.5% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 976700000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 18.3% / 33.33% · (Cash+ST Inv) / Total Assets 91.9% / 33.33% · (Cash+Recv) / Total Assets 91.9% / 33.33% · Interest income / Revenue 976700000.0% / 5% | Fail |
No. As of September 2026, Dyne Therapeutics, Inc. (DYN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Dyne Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 976700000.0% of each dividend: Dyne Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.